

























































published: 26 May 2014
doi: 10.3389/fimmu.2014.00252
Pathobiology of Salmonella, intestinal microbiota, and the
host innate immune response
Renato Lima Santos*
Departamento de Clínica e Cirurgia Veterinárias, Escola de Veterinária, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil
Edited by:
Constantino López-Macías, Mexican
Social Security Institute, Mexico;
University of Oxford, UK
Reviewed by:
Luisa Cervantes-Barragan,
Washington University School of
Medicine, USA
Kevin Maloy, University of Oxford, UK
*Correspondence:
Renato Lima Santos, Departamento
de Clínica e Cirurgia Veterinárias,
Escola de Veterinária, Universidade
Federal de Minas Gerais, Av. Antônio
Carlos 6627, Belo Horizonte, Minas
Gerais 31270-901, Brazil
e-mail: rsantos@vet.ufmg.br
Salmonella is a relevant pathogen under a clinical and public health perspective.Therefore,
there has been a significant scientific effort to learn about pathogenic determinants of
this pathogen. The clinical relevance of the disease, associated with the molecular tools
available to study Salmonella as well as suitable animal models for salmonellosis, have pro-
vided optimal conditions to drive the scientific community to generate a large expansion
of our knowledge about the pathogenesis of Salmonella-induced enterocolitis that took
place during the past two decades. This research effort has also generated a wealth of
information on the host immune mechanisms that complements gaps in the fundamental
research in this area. This review focus on how the interaction between Salmonella, the
microbiota and intestinal innate immunity leads to disease manifestation. As a highly suc-
cessful enteropathogen, Salmonella actively elicits a robust acute intestinal inflammatory
response from the host, which could theoretically lead to the pathogen demise. How-
ever, Salmonella has evolved redundant molecular machineries that renders this pathogen
highly adapted to the inflamed intestinal environment, in which Salmonella is capable of
outcompete resident commensal organisms.The adaptation of Salmonella to the inflamed
intestinal lumen associated with the massive inflammatory response that leads to diarrhea,
generate perfect conditions for transmission of the pathogen. These conditions illustrate
the complexity of the co-evolution and ecology of the pathogen, commensals, and the host.
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INTRODUCTION
Salmonella infection or the disease associated with it, salmo-
nellosis, is most often characterized by enteritis. However, host
restricted serotypes tend to induce higher levels of bacteremia,
while some human restricted serotypes cause a systemic disease
with mild enteric symptoms. All infections in warm blooded
animal species and humans are due to one single Salmonella
species, namely Salmonella enterica subsp. enterica, which includes
more than 2,400 serotypes (1). Currently, there is an effort to
reclassify S. enterica according to genotypes (based on multilo-
cus sequence typing – MSLT) rather that serotypes. MSLT may be
more accurate for predicting pathogenicity and host preferences
(2). Although human restricted serotypes (i.e., Typhi and Paraty-
phi) cause a systemic disease named typhoid fever, several other
serotypes, so-called“non-typhoidal Salmonella”(NTS) are capable
of infecting human patients causing primarily an enteric disease
characterized by enteritis and diarrhea. Most of the studies on Sal-
monella enteropathogenesis have been performed with serotype
Typhimurium, therefore, unless stated otherwise, this review refers
to Salmonella typhimurium.
Our understanding of the pathogenic mechanisms of NTS
has markedly advanced over the past 20 years. Two important
steps were crucial for achieving such advancement: (i) genetic
manipulation of the pathogen that allowed researchers to dissect
several of the Salmonella virulence factors, and (ii) development
and characterization of suitable experimental models. Thus, the
most significant molecular mechanisms employed by Salmonella
for invasion and intracellular survival in host cells have been
deciphered. Salmonella actively invades intestinal epithelial cells.
The invasion process requires several effector proteins that are
translocated through the Salmonella pathogenicity island-1 (SPI-
1)-encoded type III secretion system (TTSS) (3, 4). Salmonella is
also capable of surviving intracellularly in phagocytic and non-
phagocytic cells. Intracellular survival requires a second TTSS that
is encoded by the Salmonella pathogenicity island 2 [SPI-2; (4, 5)].
In parallel to the progress in the field of molecular microbi-
ology, experimental models, including epithelial, phagocytic, and
other cell lines (6), as well as the development of animal models
were instrumental for advancing in our knowledge on Salmonella
enteropathogenesis (7, 8). Importantly, there are marked differ-
ences on how mammalian hosts respond to Salmonella (7). The
mouse has been extensively used as a model for experimental
infections. Importantly, marked differences in natural resistance
has been demonstrated among mouse strains, which is associ-
ated with the resistant (e.g., strain 129sv) or susceptible (e.g.,
strains C57BL6/J and BALB/c) allele of the Slc11a1 (formerly
known as Nramp1) gene (9). However, inoculation of mice with
S. typhimurium results in a systemic infection that is not associ-
ated with diarrhea (7), but resembles typhoid fever caused by S.
typhimurium in human patients (10). Therefore, aside of a few
experimental reports with non-human primates (11, 12), bovine
experimental infections became very relevant in this context (13)
since cattle respond to NTS infection by developing an enteric dis-
ease that is clinically similar to human NTS infections (13, 14).

























































Santos Salmonella, microbiota, and innate immunity
Calves can be either orally infected (15) or subjected to surgical
ligation of ileal loops that allow for a more precise assessment
of early host responses (14). However, experimental studies per-
formed in the 1980s have demonstrated that the absence of the
intestinal microbiota has a profound impact on the outcome of
infection in the mouse, rendering mice much more susceptible
to infection (16). Furthermore, very early experimental studies
have demonstrated that mice treated with streptomycin had an
increased susceptibility to Salmonella (17), which allowed the
development of a mouse model of Salmonella-induced typhlocoli-
tis based on disruption of the intestinal microbiota by pre-treating
the mice with streptomycin prior to challenge with S. typhimurium
(18). This new model opened the opportunity to largely expand
animal experimentation on Salmonella-induced intestinal inflam-
mation, but it also clearly demonstrated the profound impact that
the intestinal microbiota may have on the pattern of host response
and outcome of infection.
The goal of this review is to discuss the advances in our knowl-
edge on the innate intestinal immunity under the light shed
by studies on the interaction between Salmonella, the intestinal
microbiota, and the host.
INTERDEPENDENCE OF THE INTESTINAL MICROBIOTA AND
THE IMMUNE SYSTEM
During the past few years, it has become increasingly clear that
the intestinal microbiota plays a major role modulating intestinal
mucosal immunity [reviewed by Ref. (19)]. Mammals coevolved
with a complex population of commensal microorganisms that
establish a mutually beneficial relationship to an extent that mam-
malians host more than 1014 microorganisms in the intestine (19).
The significance of the microbiota for the development of the
immune system is illustrated by the several immune defects that
are observed in germ free mice, including decreased gut-associated
lymphoid tissue, smaller mesenteric lymph nodes, and decreased
antibody production, among other structural and functional defi-
ciencies (19). It has been demonstrated that the host specific
microbiota is required for full development of the mucosal immu-
nity in the mouse (20). The Th-17 subset of T-cells is required for
homeostasis and mucosal integrity, whereas the development of
this cell population in the intestine requires the establishment of
the microbiota, since germ free mice fail to develop Th-17 in the
intestine (21). In a healthy individual, the microbiota prevents
translocation of pathogenic microorganisms to the mesenteric
lymph node thus preventing an undesirable immune response
(22). Disruption of the microbiota (known as dysbiosis) due to
antibiotic treatment favors translocation of even a non-invasive
mutant S. typhimurium strain by phagocytes to the mesenteric
lymph node (22).
In the past few years, a large number of relevant scientific
reports have clearly established how the pathogen-associated mol-
ecular patterns (PAMPs) are recognized by their hosts (rang-
ing from insects to mammalians) through pathogen recognition
receptors (PRRs). However, a more recent wave of experimen-
tal evidences support the notion that molecules derived from the
commensal microbiota are constantly sensed by host PRRs, which
is a key step in establishing homeostasis [reviewed by Ref. (23)].
MyD88, a key adaptor protein for most TLRs (toll-like receptors),
has been shown to play an important role in this context, since mice
lacking MyD88 have a 100-fold increase in the number of bacteria
associated with the intestinal mucosa (24). Therefore, consider-
ing that commensal microbiota is also sensed by PRRs, the term
MAMPs, which stands for microbe-associated molecular patterns,
has been proposed (25). Divergence between a PRR-mediated
inflammatory response and PRR-mediated immune modulation
and homeostasis is dependent on the concurrent presence of addi-
tional signals such as stimulation of cytosolic receptors by MAMPs
(26). Importantly, in addition to sensing MAMPs, some of the
cytosolic PRRs [i.e., Nod-like receptors (NLRs)] are capable of
sensing signals associated with cell stress and damage, such as
potassium influx, reactive oxygen species, membrane damage, etc.
These signals are named danger-associated molecular patterns
(DAMPs). Therefore, concomitant stimulation of extracellular
PRRs and cytosolic PRRs by MAMPs or DAMPs allows the innate
immune system to differentiate between stimuli from the com-
mensal microbiota leading to homeostasis or pathogen triggered
responses that lead to inflammation [reviewed by Ref. (27)].
While the establishment of the intestinal microbiota is a key
event for immune maturation, conversely, immune cells in the
intestine play an active role in shaping the composition of the
microbiota, leading to homeostasis [reviewed by Ref. (28)]. For
instance, the absence of CD4+ Treg cells results in an unregulated
T-cell response against antigens from the microbiota, which causes
intestinal inflammation (29). Mucosal antibodies, i.e., secretory
IgA, also play a central role in shaping the microbiota. Impaired
production of high affinity secretory IgA in the intestinal mucosa
results in dysbiosis (30). Another very important component of
this interaction between the host and microbiota are the intesti-
nal epithelial cells (i.e., enterocytes, goblet cells, and Paneth cells).
In addition to a physical barrier, structured by tight junctions
between these cells that completely separate the apical from the
basolateral compartment, the epithelium generates important fac-
tors that modulates expansion and composition of the microbiota.
Goblet cells produce large amount of mucous that is a key element
in homeostasis, while other cell types, particularly Paneth cells,
generate antimicrobial peptides (31).
Interestingly, the influence of the microbiota is not restricted
to the intestinal mucosal immunity, but it also impacts systemic
immune sites. Antibiotic-induced dysbiosis results in impaired
immune response against the influenza virus, while under these
circumstances immunity is restored by rectal administration of
PPR ligands, indicating that exposure of the intestinal mucosa to
MAMPs is critical to modulating immunity (32). Indeed, there
are experimental evidences of translocation of MAMPs from the
intestine to systemic sites, where it modulates immune maturation,
which indicates that the immune modulator role of the intestinal
microbiota is not restricted to local tissues, influencing other dis-
tant immune organs (33). Interaction of the microbiota with the
immune system is extremely complex, to the point that the micro-
biota may either favor or prevent the development of autoimmune
disorders (34) as well as cancer development (35). Furthermore,
the microbiota influences numerous other pleiotropic effects,
both on pathologic events such as asthma, arthritis, inflamma-
tory bowel diseases, obesity, and cardiovascular disease, as well
as on physiological functions including organ morphogenesis,
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intestinal vascularization, tissue regeneration, bone homeostasis,
metabolism, and behavior (36).
SALMONELLA INTERACTION WITH THE INTESTINAL
MICROBIOTA
As previously mentioned, earlier studies have clearly demon-
strated that disruption of the intestinal microbiota by treating
mice with streptomycin results in increased susceptibility to Sal-
monella infection (17). Furthermore, the intestinal microbiota has
a protective effect against Salmonella infection in the mouse (16).
These studies prompted Barthel et al. (18) to develop a very useful
experimental model based on treatment of mice with strepto-
mycin followed by challenge with S. typhimurium. This model
has been extensively utilized by the entire field, since experimental
infections were previously largely restricted to more expensive and
labor intensive animal models such as oral infections in calves (15)
or the bovine ligated ileal loops (14). Further studies demonstrated
that Salmonella elicits an inflammatory response in streptomycin-
treated mice that is pretty similar to that observed in Salmonella-
infected germ free mice (37). While S. typhimurium infection in
cattle triggers an acute inflammatory response that is characterized
by massive infiltration of neutrophils (Figure 1) associated with
variable degrees of necrosis, hemorrhage, erosion, and fibrinous
pseudomembrane formation over the intestinal mucosa, particu-
larly at the ileal Peyer’s patches (14, 15), the same pathogen in the
mouse does not elicit significant neutrophilic infiltration in the
intestinal mucosa (7). Mice respond to S. typhimurium infection
with a mild histiocytic infiltration, but in contrast they develop
a marked systemic infection that is associated with lesions in the
liver and spleen in the absence of diarrhea. Therefore, the develop-
ment of the streptomycin-treated mouse model largely broadened
the possibilities for in vivo experimental study of salmonellosis,
allowing a marked worldwide expansion of animal experiments
among several groups as well as genetic manipulation not just of
the pathogen, but also of the host. Pretreatment with streptomycin
results in a severe acute inflammatory response of the intestinal
mucosa in response to S. typhimurium infection (Figure 2) (18).
Although the original study that described this model demon-
strated that streptomycin-treated mice have a much more efficient
intestinal colonization with S. typhimurium (18), which suggests
that the mechanism is likely due to lack of competition with com-
ponents of the microbiota, this did not prove any direct cause or
effect relationship between composition of the microbiota and
the intrinsic nature of the innate intestinal immune response.
Therefore, this model opened another extremely important area
of investigation in this field, i.e., the role of the microbiota in the
pathogenesis of NTS-induced enterocolitis.
Clinical treatment of human patients with antibiotics is rec-
ognized as a risk factor for subsequent Salmonella infection
(38), which correlates well with what we have learned from the
streptomycin-treated mouse model of Salmonella infection (18).
However, the interaction of Salmonella with the microbiota is
complex, and under certain circumstances pathogen and com-
mensal may not necessarily have a mutually excluding relationship.
For instance, a recent study demonstrated that carbohydrates
metabolized by commensal microorganisms may serve as energy
source for Salmonella. In that study, Bacteroides thetaiotaomicron,
FIGURE 1 | Salmonella-induced enteritis in experimentally infected
ligated ileal loops in calves. (A) Uninfected loop with no inflammatory
reaction; 10× objective. (B) Higher magnification of uninfected loop; 40×
objective. (C) Salmonella-infected loop with a severe and diffuse
inflammatory infiltrate and blunting of the villi; 10× objective. (D) Higher
magnification showing a diffuse and severe infiltration of neutrophils; 40×
objective. Hematoxylin and eosin.
which encodes sialidase that is required to release sialic acid from
glycoconjugates, but does not have the enzymatic machinery to
utilize sialic acid as a carbon source, generates free sialic acid,
whereas S. typhimurium that lacks sialidase is capable of catabo-
lizing this carbohydrate (39). S. typhimurium can also metabolize
fucose generated in a similar manner. Therefore, members of the
commensal microbiota are capable of releasing carbon sources that
themselves cannot utilize, but that can be used as energy source
by Salmonella (39). This process is thought to play a role in post
antibiotic expansion of enteropathogens (39).
Susceptibility to different enteric pathogens is highly variable
among different age groups. Interestingly, these differences in
susceptibility may at least in part be related to changes in the
composition of the intestinal microbiota [reviewed by Ref. (40)].
During early infancy the microbiota is highly dynamic, whereas
in adults it is much more stable and composed predominantly by
the phylum Bacteroidetes and Firmicutes (approximately 95% of
the microbiota), and elderly tend to have a predisposition to mild
inflammation in the intestinal mucosa and decrease in the relative
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FIGURE 2 | Salmonella-induced typhlitis in mice with dysbiotic
microbiota due to streptomycin treatment. (A) Marked thickening of the
cecal wall with edema and increased cellularity due to a diffuse infiltration
of inflammatory cells in a mouse with dysbiosis (pre-treated with
streptomycin) and intragastrically infected with Salmonella enterica
serotype Typhimurium. (B) Section of the cecum from a mouse
intragastrically infected with Salmonella enterica serotype Typhimurium in
the presence of a normal microbiota with no histopathological changes.
(C) Section of the cecum from a healthy non-infected mouse. Note that all
micrographs have the same magnification 20× objective. Hematoxylin and
eosin.
abundance of Actinobacteria (essentially Bifidobacteria) and Fir-
micutes (40). Importantly, early and late stages of life, when the
intestinal microbiota is less stable, with relatively lower numbers
of Bacteroidetes and relatively higher numbers of gamma Pro-
teobacteria, correspond to the period of higher susceptibility to
some enteric pathogens (40).
With an elegant experimental approach, Chung et al. (20)
demonstrated that germ free mice associated with human intesti-
nal microbiota have increased susceptibility to Salmonella when
compared to mice that had been associated with a normal mouse
microbiota, indicating that under those experimental conditions
the mouse microbiota is more protective against Salmonella than
the human counterpart. This somewhat parallels the manifes-
tation of Salmonella-induced intestinal pathology in these two
host species, supporting the notion that the human microbiota
may favor Salmonella-elicited intestinal inflammation, whereas
the murine microbiota impairs the ability of Salmonella for trig-
gering a host inflammatory reaction (7), which may be due to
a lower antagonistic potential of the human microbiota when
compared to that of mice.
An increasing number of experimental evidences points toward
the notion that Salmonella has evolved multiple mechanisms by
which it can overgrow members of the microbiota under condi-
tions of an inflamed intestine (41). Several studies have identified
Salmonella effectors, among other bacterial factors, that play a
role in triggering host inflammation in the intestine (42). Salmo-
nella-induced enteropathogenesis is strongly associated with the
ability of the pathogen to invade epithelial cells and the intesti-
nal mucosa. Therefore, five effector proteins translocated through
the (SPI-1)-encoded TTSS, namely SipA, SopA, SopB, SopD, and
SopE2, are required for invasion and enteropathogenesis (43).
Earlier studies have demonstrated that Salmonella has a com-
petitive advantage over the microbiota in the inflamed intestine,
whereas such advantage does not take place in the absence of
inflammation (44). Quite a few mechanisms by which Salmo-
nella takes advantage of intestinal inflammation have emerged
recently. Lipocalin-2, a host antimicrobial peptide, is gener-
ated in the inflamed intestine in response to IL-17 and IL-22,
whose production is triggered by Salmonella infection. This pep-
tide prevents iron acquisition by intestinal microorganisms. It
binds enterobactin, a siderophore produced by several enteric
bacteria. However, Salmonella produces salmochelin (in addi-
tion to enterobactin), another siderophore that is not bound by
lipocalin-2. Thus, under conditions of inflammation and abun-
dance of lipocalin-2, Salmonella has a competitive advantage over
other intestinal bacteria (45). Iron deprivation in the inflamed
intestine induces expression of colicin Ib by Salmonella, which
is a bacteriocin active against other Enterobacteriaceae, provid-
ing additional competitive advantage to Salmonella against part
of the commensal microbiota under inflammatory conditions
(46). Among other mechanisms by which Salmonella overgrow
the commensal microbiota in the inflamed intestinal environ-
ment is based on its ability to acquire microelements, includ-
ing zinc (47). In the inflamed intestine, calprotectin produced
by neutrophils inhibits bacterial growth by sequestering zinc.
However, Salmonella is capable of evading this host protective
mechanism by expressing a high affinity zinc transporter named
ZnuABC (47).
Another striking example of Salmonella adaptation to intesti-
nal inflammation was provided by Winter et al. (48), who
demonstrated that the inflamed intestinal environment provides
a respiratory electron acceptor for Salmonella. Tetrathionate has
been used as an enrichment medium for Salmonella isolation
in vitro from samples containing competitive microbes since the
1920s. Reactive oxygen species generated during the inflammatory
process triggered by Salmonella itself, oxidizes endogenous thio-
sulfate to generate tetrathionate, which can then be utilized as an
anaerobic respiratory electron acceptor by Salmonella (48). This
mechanism provides competitive advantage for Salmonella in the
inflamed intestine while members of the microbiota perish due
to environmental changes resulting from the massive Salmonella-
induced inflammatory response. Salmonella-induced inflamma-
tion is associated with detachment of large numbers of enterocytes
from the mucosa (14), Interestingly, ethanolamine derived from
phosphatidylethanolamine, the most abundant phospholipid in
membranes of detached enterocytes, can be utilized by Salmo-
nella under anaerobic conditions using tetrathionate as electron
acceptor in the inflamed gut (49). In addition to tetrathionate
respiration, the effector protein SopE induces nitrate produc-
tion by the host, which favors growth of Salmonella by allowing
anaerobic nitrate respiration (50). Neutrophil-derived elastase,
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which is abundant in the inflamed intestine, suppresses compo-
nents of the commensal microbiota, favoring intestinal growth
of Salmonella (51). Mechanisms of Salmonella adaptation to the
inflamed intestinal environment have been recently reviewed by
Winter and Bäumler (52).
As a component of the innate host immune response, the
inflammatory process should be seen as a host mechanism for
preventing the spread of infection, which to some extent is com-
pletely correct, since in the absence of a neutrophilic response,
Salmonella tends to spread more efficiently to systemic sites of
infection, both in the mouse (53) as well as in cattle (54). These
experimental observations parallel clinical disease since serotype
Typhi that causes systemic infections does not elicit a significant
intestinal neutrophilic response (10). However, as paradoxically
as it may first seem, Salmonella evolved to take advantage of the
host intestinal inflammatory response. Together, the studies dis-
cussed above clearly support the notion that Salmonella-induced
inflammation is part of this pathogen strategy to create a highly
favorable environment in the intestinal lumen for its own multipli-
cation. However, Salmonella is a facultative intracellular pathogen,
and that interaction with host cells is a determinant of the path-
ogenic capacity of this organism. Earlier studies strongly focused
on the interaction of Salmonella with different host cell types,
both in vitro and in vivo (6), missing a very important aspect of
the big picture, which is the fact that only a fraction of the Sal-
monella population in a given host actually invades the mucosa
during the acute phase of infection, while most of the organ-
isms remain in the intestinal lumen (41). Excessive invasion of
the intestinal mucosa by a larger fraction of the population of
Salmonella could not be desirable under the pathogen point of
view, since once within the host tissues, Salmonella is exposed to
several efficient bactericidal mechanisms. This may explain the
role of the SptP effector protein that reverses some of the molecu-
lar mechanisms used by Salmonella to invade intestinal epithelial
cells (55).
Summarizing, Salmonella uses a kamikaze strategy based on
a small fraction of its infecting population actively invading and
triggering a massive acute inflammatory response. While this acute
neutrophilic response may effectively restrict the infection mostly
to enteric sites, largely preventing survival of invasive bacteria, and
therefore preventing systemic dissemination of the pathogen, it
also creates an intraluminal intestinal environment that favors the
remaining larger fraction of the pathogen population that stays in
the intestinal lumen, being able to multiply and effectively transmit
the infection to the next host.
MANIPULATION OF THE MICROBIOTA FOR PROPHYLACTIC
AND THERAPEUTIC PURPOSES
A thorough review of prophylactic and therapeutic approaches
to modulate the function and/or composition of the microbiota is
completely beyond the scope of this article. However, under a clin-
ical point of view, it is relevant to point out some of the advances in
this area. Clinical applications of probiotic and prebiotic has been
recently reviewed by Vieira et al. (56). Probiotics are defined as live
microorganisms which when administered in adequate amounts
confer health benefits to the host [FAO/WHO, 2002 FAO/WHO
Working Group, Guidelines for the Evaluation of Probiotics in
Food (2002). London, ON, Canada]. The notion of probiotic
has been developed long time ago with the original observations
of Metchnikoff in the beginning of the twentieth century, who
identified microorganisms, particularly Bacillus bulgaricus (cur-
rently named Lactobacillus bulgaricus), which has beneficial effects
on health and was the foundation of the yogurt industry (57).
Probiotics, including different formulations and several different
microorganisms in variable combinations, such as Saccharomyces
boulardii, Bifidobacterium spp., Streptococcus thermophilus, Lacto-
bacillus spp., Escherichia coli strain Nissle 1917, among several
other microorganisms have been extensively used experimentally
or therapeutically for treating enteric diseases with predominantly
positive outcomes (56). However, particularly in immune compro-
mised patients, the risk of sepsis should be taken in account when
electing a probiotic therapeutic protocol (58). Prebiotics are food
ingredients that are not digestible by the host and have favorable
effects on specific components of the microbiota and intestinal
homeostasis, although this concept may be expanded to include
other food ingredients that do not completely fit the criteria for
a prebiotic, but have similar effects, such as dietary fibers. Thera-
peutic or prophylactic combinations of probiotics and prebiotics
are termed symbiotics (56).
A similar concept is linked to the ancient therapeutic practice of
adoptive transfer of commensal microbiota from healthy individ-
uals to patients with enteric diseases, particularly those associated
with antibiotic therapy, which may be successful under certain
conditions (59).
Specifically considering salmonellosis, there are experimen-
tal evidences indicating that probiotics may have a protective
effect in mice experimentally challenged with Salmonella. Both
germ free and conventional mice pre-treated with Saccharomyces
cerevisiae UFMG 905 had lower levels of S. typhimurium dissem-
ination upon experimental infection (60). Similarly, Lactobacillus
acidophilus has protective effects against S. enteritidis infection
in the mouse (61). Although it is not clear whether probiotics
will ever have useful therapeutic applications in human patients
infected with Salmonella, these experimental studies are relevant
since probiotics and prebiotics have a significant potential for the
animal industry, particularly for poultry and pigs. In food pro-
ducing animal species, probiotics and prebiotics may prevent a
high burden of Salmonella, thus mitigating the risk of transmis-
sion, with the additional significant benefit of decreasing the need
and therefore the exposure of food producing animals to antibi-
otic treatment and growth promoters, which prevent emergence
of antibiotic-resistant strains of pathogens. Indeed, several probi-
otics as well as food additives have been extensively studied under
field conditions, but the results are highly variable, and strongly
influenced by management, nutrition, environmental conditions,
and obviously the levels of Salmonella challenge. Therefore, a gen-
eral recommendation or a well-established protocol for probiotic
or prebiotic prevention of Salmonella infection in farm animals is
still unavailable (62, 63).
CONCLUDING REMARKS AND PERSPECTIVES
Since the first identification of microorganisms of the genus Sal-
monella in the beginning of the last century, a large body of knowl-
edge has been accumulated regarding microbiological features of
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the organism, disease manifestation in different host species as
well as its epidemiological implications. However, it was only
during the last decade of the past century that molecular tools
became available for dissecting pathogenic mechanisms of Salmo-
nella. These molecular approaches preceded more sophisticated
animal models, and therefore the pioneer investigations on Sal-
monella pathogenesis pictured a pathogen highly specialized in
invasion and induction of a host response, as if the pathogen was
indifferent to the myriad of commensal microorganisms in the
intestinal environment. A subsequent wave of well-designed stud-
ies began to reveal, at a mechanistic level, some of the interactions
between Salmonella and the microbiota in the intestine. Currently,
it is clear that the complexity of these processes is unimaginable at
this point so this is still a broadly open field for scientific investi-
gation. A deeper knowledge of the pathobiology of Salmonella in
the context of the intestinal environment may certainly open new
perspectives for therapeutic approaches as well as for controlling
animal and human salmonellosis.
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